COVID-19 VACCINE INFORMATION
Learn more about the vaccine and how it can help protect you and your family from COVID-19.
Pre and Post Vaccine Documents
Health Care Provider Education Documents
Ministry of Health Statement
FREQUENTLY ASKED QUESTIONS:
According to NACI guidelines and Pfizer, every attempt should be made to give the BioNTech COVID 19 vaccine at the recommended 21-day interval. However, NACI guidelines recommend a schedule option of no sooner than 19 days and no later than 28 days. There is no data on the maximum interval between doses and their efficacy and therefore, every effort should be made to meet the recommended dosing guidelines. The NACI guidelines suggest that in general, regardless of the interruption time, there is no need to restart the dosing series.
Both Pfizer and NACI guidelines state that if a client had a vaccine (including a vaccine for influenza) within 14 days of the scheduled date of the BioNTech COVID 19 vaccine, then the BioNTech COVID 19 vaccine should be delayed until the 14 day period has passed.
If a client has had the BioNTech COVID 19 vaccine series, another vaccine should not be administered within 28 days of the last dose (except in the case of post-exposure prophylaxis) due to elicitation of inflammatory cytokine response.
According to NACI guidelines, individuals on long-term anticoagulation are not at a significant risk for bleed and can receive the vaccine.
|Yes. You still receive your second dose unless you yourself are positive. See next question and answer if you yourself become positive between doses.
|You should wait until you are clear of symptoms and Public Health has cleared you from self-isolation before receiving the second dose.
NACI guidelines state:
As a precautionary measure and in light of the need to be able to monitor for COVID-19 vaccine adverse events without potential confounding from symptoms of COVID-19 or other co-existing illnesses, it would be prudent to wait until all symptoms of an acute illness are completely resolved before vaccinating with an authorized COVID-19 vaccine
NACI guidelines state further:
If the administration of the second dose of a COVID-19 vaccine is delayed, the second dose should be provided as soon as possible. Currently, no data on a maximum interval between doses or on medium- or long-term efficacy of COVID-19 vaccines are available. Therefore, every effort should be made to vaccinate with the second dose according to the recommended schedule.
In general, regardless of the time between doses, interruption of a vaccine series does not require restarting the series as delays between doses do not result in a reduction in final antibody concentrations for most multi-dose products. However, the follow-up time in COVID-19 vaccine clinical trials is short and maximum protection may not be attained until the complete vaccine series has been administered.